SCHEMBL6031390

SCHEMBL6031390

O=c1ccnc(N2CCCN2)o1

nearest known ligand 0.31

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 1/20 0.30
PRKX P51817 1/20 0.30
PRKCE Q02156 1/20 0.30
PRKCD Q05655 1/20 0.30
ROCK1 Q13464 1/20 0.30
PRKD1 Q15139 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6032448 0.78 HTR2C (0.44)
SCHEMBL6032833 0.78 ELANE (0.42)
SCHEMBL6031928 0.76 ELANE (0.44)
SCHEMBL6423951 0.76 HTR2C (0.32)
SCHEMBL914723 0.72
SCHEMBL6031750 0.71 ELANE (0.45)
SCHEMBL28486034 0.64 ALDH1A1 (0.50)
SCHEMBL14921731 0.64 MEN1 (0.36)
SCHEMBL28290847 0.62 ADRB2 (0.53) ROCK2ROCK1
SCHEMBL28179378 0.62 HSD11B1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1631295-A2 USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER Arexis AB (SE) 2006-03-08 EP disclosed
WO-2004108139-A2 USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER AREXIS AB (SE) 2004-12-16 WO disclosed